About Us

Our immunotherapeutics represent a new class of drug that we believe has the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and possibly extend longevity. 

While chronic inflammation is possible at any age, it is more common as we age. In this case, the condition is known as inflammaging. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to the cause for senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as indications that impact quality-of-life that are not life-threatening.  

The Company has developed two different drug discovery and development platforms, our legacy TOBI™ (Tissue factOr-Based fusIon) platform and our newly developed targeted platform technology – TRBC platform. 

The TOBI platform is designed to engineer multi-functional fusion protein molecules and protein complexes. It employs a Tissue Factor (TF) scaffold that can be packaged with multiple protein targets, including cytokines, chemokines, ligands, receptors, and single-chain antibodies. 

The Company invented its second-generation platform, TRBC platform technology, to create novel immunotherapeutics to treat diseases, including cancer, as well as improve quality-of-life conditions. These immunotherapeutics, which include multi-specific cytokines, targeted second-generation immune checkpoint inhibitors, and immune-cell engagers, have the capabilities to activate subsets of immune cells that specifically target cancerous or infected cells.

Our clinical development program is based on a few select lead product candidates which will be evaluated in Company-sponsored clinical trials in autoimmune disorders, solid tumors and quality-of-life conditions. We have a large portfolio of non-core programs and assets and for these, clinical development will be conducted throughout licensing agreements and other business development transactions.

HCWB has an experienced team led by Dr. Hing C. Wong, our Founder and CEO, who discovered and developed Anktiva^® immunotherapeutic (also known as ALT-803, an IL-15 agonist receptor) through pivotal trial. This blockbuster immunotherapeutic for cancer was sold to ImmunityBio, Inc. in 2017 in a $1.0 billion acquisition. Anktiva^® was approved by FDA for bladder cancer indication in 2024.